IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses - PubMed (original) (raw)
IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses
María Moreno et al. J Immunol. 2008.
Abstract
CD1d-restricted invariant NKT (iNKT) cells can enhance immunity to cancer or prevent autoimmunity, depending on the cytokine profile secreted. Antitumor effects of the iNKT cell ligand alpha-galactosylceramide (alphaGC) and iNKT cell adoptive transfer have been demonstrated in various tumor models. Together with reduced numbers of iNKT cells in cancer patients, which have been linked to poor clinical outcome, these data suggest that cancer patients may benefit from therapy aiming at iNKT cell proliferation and activation. Herein we present results of investigations on the effects of human iNKT cells on Ag-specific CTL responses. iNKT cells were expanded using alphaGC-pulsed allogeneic DC derived from the acute myeloid leukemia cell line MUTZ-3, transduced with CD1d to enhance iNKT cell stimulation, and with IL-12 to stimulate type 1 cytokine production. Enhanced activation and increased IFN-gamma production was observed in iNKT cells, irrespective of CD4 expression, upon stimulation with IL-12-overexpressing dendritic cells. IL-12-stimulated iNKT cells strongly enhanced the MART-1 (melanoma Ag recognized by T cell 1)-specific CD8(+) CTL response, which was dependent on iNKT cell-derived IFN-gamma. Furthermore, autologous IL-12-overexpressing dendritic cells, loaded with Ag as well as alphaGC, was superior in stimulating both iNKT cells and Ag-specific CTL. This study shows that IL-12-overexpressing allogeneic dendritic cells expand IFN-gamma-producing iNKT cells, which may be more effective against tumors in vivo. Furthermore, the efficacy of autologous Ag-loaded DC vaccines may well be enhanced by IL-12 overexpression and loading with alphaGC.
Similar articles
- NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt R, Harris AL, Old L, Cerundolo V. Hermans IF, et al. J Immunol. 2003 Nov 15;171(10):5140-7. doi: 10.4049/jimmunol.171.10.5140. J Immunol. 2003. PMID: 14607913 - NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
Stober D, Jomantaite I, Schirmbeck R, Reimann J. Stober D, et al. J Immunol. 2003 Mar 1;170(5):2540-8. doi: 10.4049/jimmunol.170.5.2540. J Immunol. 2003. PMID: 12594280 - Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells.
van der Vliet HJ, Wang R, Yue SC, Koon HB, Balk SP, Exley MA. van der Vliet HJ, et al. J Immunol. 2008 Jun 1;180(11):7287-93. doi: 10.4049/jimmunol.180.11.7287. J Immunol. 2008. PMID: 18490728 Free PMC article. - Application of natural killer T cells in antitumor immunotherapy.
Hong C, Park SH. Hong C, et al. Crit Rev Immunol. 2007;27(6):511-25. doi: 10.1615/critrevimmunol.v27.i6.20. Crit Rev Immunol. 2007. PMID: 18197797 Review.
Cited by
- Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies.
Srivastava S, Tyagi A, Pawar VA, Khan NH, Arora K, Verma C, Kumar V. Srivastava S, et al. Immunotargets Ther. 2024 Aug 27;13:413-433. doi: 10.2147/ITT.S474659. eCollection 2024. Immunotargets Ther. 2024. PMID: 39219644 Free PMC article. Review. - [Advances in Pseudoprogression of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer].
Tong Y, Long Y, Zhang F, Li J. Tong Y, et al. Zhongguo Fei Ai Za Zhi. 2024 Apr 20;27(4):306-320. doi: 10.3779/j.issn.1009-3419.2024.101.10. Zhongguo Fei Ai Za Zhi. 2024. PMID: 38769834 Free PMC article. Review. Chinese. - Lactate in the tumor microenvironment: A rising star for targeted tumor therapy.
Li Z, Wang Q, Huang X, Yang M, Zhou S, Li Z, Fang Z, Tang Y, Chen Q, Hou H, Li L, Fei F, Wang Q, Wu Y, Gong A. Li Z, et al. Front Nutr. 2023 Feb 16;10:1113739. doi: 10.3389/fnut.2023.1113739. eCollection 2023. Front Nutr. 2023. PMID: 36875841 Free PMC article. Review. - Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance.
Qin Y, Xu G. Qin Y, et al. Front Immunol. 2022 Dec 8;13:1053120. doi: 10.3389/fimmu.2022.1053120. eCollection 2022. Front Immunol. 2022. PMID: 36569859 Free PMC article. Review. - Invariant NKT Cells Promote the Development of Highly Cytotoxic Multipotent CXCR3+CCR4+CD8+ T Cells That Mediate Rapid Hepatocyte Allograft Rejection.
Zimmerer JM, Ringwald BA, Chaudhari SR, Han J, Peterson CM, Warren RT, Hart MM, Abdel-Rasoul M, Bumgardner GL. Zimmerer JM, et al. J Immunol. 2021 Dec 15;207(12):3107-3121. doi: 10.4049/jimmunol.2100334. Epub 2021 Nov 22. J Immunol. 2021. PMID: 34810223 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials